Drug name - Zepzelca

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7763615 JAZZ Ecteinascidin analogs for use as antitumour agents
Dec, 2024

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 15, 2025
Orphan Drug Exclusivity (ODE) Jun 15, 2027

Drugs and Companies using LURBINECTEDIN ingredient

Market Authorisation Date: 15 June, 2020

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
4MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in